MedTrace Logo

Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection

NCT02281266 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2014-11-21

No results posted yet for this study

Summary

Efficacy and safety of Thymalfasin adjuvant therapy in HBV-related HCC after curative resection.

Conditions

  • Curable Hepatitis B Virus-Related Hepatocellular Carcinoma

Interventions

PROCEDURE

curative resection

DRUG

thymalfasin

1.6mg twice a week, 12 months

DRUG

nucleoside analog (suggest to use entecavir)

Sponsors & Collaborators

  • SciClone Pharmaceuticals

    collaborator INDUSTRY

  • Jia Fan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2018-06-30
Completion
2018-10-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02281266 on ClinicalTrials.gov